Evidence map›Paper›PMID 27294846›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2016

Multifunctional Transmembrane Protein Ligands for Cell-Specific Targeting of Plasma Membrane-Derived Vesicles.

Chi Zhao, David J Busch, Connor P Vershel, Jeanne C Stachowiak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Extracellular vesicle-based drug delivery in cancer immunotherapy.Drug delivery and translational research · 2023
    Review
  8. Review
  9. Gap Junction-Mediated Delivery of Polymeric Macromolecules.ACS biomaterials science & engineering · 2022
    Article
  10. Review
  11. Strategies to functionalize extracellular vesicles against HER2 for anticancer activity.Extracellular vesicles and circulating nucleic acids · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Role of extracellular vesicles in tumour microenvironment.Cell communication and signaling : CCS · 2020
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chi ZhaoDepartment of Biomedical Engineering, Institute for Cellular and Molecular Biology, The University of Texas at Austin, TX, 78712, USA.
David J BuschDepartment of Biomedical Engineering, Institute for Cellular and Molecular Biology, The University of Texas at Austin, TX, 78712, USA.
Connor P VershelDepartment of Biomedical Engineering, Institute for Cellular and Molecular Biology, The University of Texas at Austin, TX, 78712, USA.
Jeanne C StachowiakDepartment of Biomedical Engineering, Institute for Cellular and Molecular Biology, The University of Texas at Austin, TX, 78712, USA.
The University of Texas at Austin · US

Funding

Protein Networks as Synergistic Drivers of Membrane TrafficR01GM112065 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI STACHOWIAK, JEANNE CASSTEVENS · 2014 to 2020
$2.5M
NIGMS NIH HHS R01 GM112065
6 · The paper itself

Abstract

Liposomes and nanoparticles that bind selectively to cell-surface receptors can target specific populations of cells. However, chemical conjugation of ligands to these particles is difficult to control, frequently limiting ligand uniformity and complexity. In contrast, the surfaces of living cells are decorated with highly uniform populations of sophisticated transmembrane proteins. Toward harnessing cellular capabilities, here it is demonstrated that plasma membrane vesicles (PMVs) derived from donor cells can display engineered transmembrane protein ligands that precisely target cells on the basis of receptor expression. These multifunctional targeting proteins incorporate (i) a protein ligand, (ii) an intrinsically disordered protein spacer to make the ligand sterically accessible, and (iii) a fluorescent protein domain that enables quantification of the ligand density on the PMV surface. PMVs that display targeting proteins with affinity for the epidermal growth factor receptor (EGFR) bind at increasing concentrations to breast cancer cells that express increasing levels of EGFR. Further, as an example of the generality of this approach, PMVs expressing a single-domain antibody against green fluorescence protein (eGFP) bind to cells expressing eGFP-tagged receptors with a selectivity of ≈50:1. The results demonstrate the versatility of PMVs as cell targeting systems, suggesting diverse applications from drug delivery to tissue engineering.

Indexed as

AnimalsCell Line, TumorCell MembraneCHO CellsCricetulusDrug Delivery SystemsErbB ReceptorsHumansLiposomesTissue EngineeringErbB ReceptorsLiposomesbiomaterialscell targetingextracellular vesiclesprotein engineering

Identifiers

PMID27294846
PMCPMC5523125
OpenAlexW2443861673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.